Key result
Switching from oral to transdermal estradiol therapy significantly increased serum IGF-I levels from 18.7 to 23.4 nmol/L (P=0.008) in women with GH and LH deficiency on stable GH therapy.
Why the study?
Does switching from oral to transdermal estradiol increase serum IGF-I concentrations in women with GH deficiency on stable GH therapy?
Population
6 females with growth hormone deficiency (GHD) and LH deficiency on stable GH therapy
Comparison
Transdermal estradiol 50 microg/day vs Oral estradiol 2 mg/day
Design
Case_series
Follow-up
5 cycles
Authors
Loading...
May raise IGF-I in GHD women switched from oral to transdermal estrogen; leaves open effects on clinical outcomes.
Does switching from oral to transdermal estradiol increase serum IGF-I concentrations in women with GH deficiency on stable GH therapy?
Absolute Event Rate: 23.4% vs 18.7%
p-value: p=0.008
Switching from oral to transdermal estradiol therapy increases serum IGF-I levels in women with GH deficiency, suggesting altered GH potency based on the route of estrogen administration.
Janssen et al. (2000) studied Growth hormone (GH) deficiency and LH deficiency (n=6). Transdermal 17β-estradiol vs. Oral estradiol (2 mg/day) was evaluated on Serum IGF-I levels (p=0.008). Switching from oral to transdermal estradiol therapy significantly increased serum IGF-I levels from 18.7 to 23.4 nmol/L (P=0.008) in women with GH and LH deficiency on stable GH therapy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: